Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Selinexor/Dexamethasone Combo Approved in UK for Relapsed/Refractory Myeloma

June 2nd 2021

The United Kingdom’s Medicines & Healthcare Products Regulatory Agency has granted conditional marketing authorization to the combination of selinexor and dexamethasone as a treatment for select patients with relapsed/refractory multiple myeloma.

Adjuvant Neoantigen Peptide Vaccine PGV-001 Shows Promise in Multiple Malignancies

June 2nd 2021

A personalized adjuvant neoantigen peptide vaccine, PGV-001, was successfully synthesized and administered to patients across a wide range of malignancies who had a greater than 30% chance of disease recurrence.

FDA Grants Breakthrough Status to Teclistamab for Relapsed/Refractory Multiple Myeloma

June 1st 2021

The FDA has granted a breakthrough therapy designation to teclistamab for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Ghosh on the Role of Ide-Cel in Relapsed/Refractory Multiple Myeloma

June 1st 2021

Monalisa Ghosh, MD, discusses the role of idecabtagene vicleucel in relapsed/refractory multiple myeloma landscape.

Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma

May 31st 2021

Dr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.

Dr. Morgan on Optimizing Treatment in Ultra High–Risk Multiple Myeloma

May 27th 2021

Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.

Melphalan Flufenamide Noninferior to Pomalidomide in Relapsed/Refractory Myeloma

May 26th 2021

Melphalan flufenamide has been shown to be noninferior to pomalidomide in the treatment of patients with relapsed/refractory multiple myeloma.

Novel Therapies Under Study for Triple-Class Refractory Multiple Myeloma

May 25th 2021

Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.

Addressing Unmet Needs for Triple-Class Refractory Multiple Myeloma

May 25th 2021

Current unmet needs surrounding the management of patients with triple-class refractory multiple myeloma with newer novel therapies.

Individualizing Therapy for Triple-Class Refractory Myeloma

May 25th 2021

Guidance regarding proper treatment selection and sequencing of therapies for triple-class refractory multiple myeloma.

Dr. Ghosh on the Impact of Ide-Cel in Relapsed/Refractory Multiple Myeloma

May 25th 2021

Monalisa Ghosh, MD, discusses the impact of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Dr. Diamond on the Need to Integrate MRD Testing Into Clinical Trials in Multiple Myeloma

May 21st 2021

Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.

Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

May 20th 2021

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Dr. Pianko on the Role of Daratumumab in Frontline Myeloma

May 18th 2021

Matthew James Pianko, MD, discusses the role of daratumumab in the frontline treatment of multiple myeloma.

Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 Era

May 18th 2021

Silver linings of the COVID-19 pandemic have opened the door for new opportunities for decentralized clinical trials and real-world data in a post–COVID-19 world.

Single-Agent Belantamab Mafodotin for Triple-Class Refractory Multiple Myeloma

May 18th 2021

An overview of the DREAMM-2 study of belantamab mafodotin for triple-class refractory patients with multiple myeloma, with special considerations for managing treatment-related corneal events.

Melflufen and Dexamethasone for Triple-Class Refractory Multiple Myeloma

May 18th 2021

The rationale for adding melflufen to dexamethasone as treatment for patients with triple-class refractory multiple myeloma.

CAR T-Cell Therapy UCARTCS1A Shows Early Activity in Relapsed/Refractory Myeloma

May 14th 2021

UCARTCS1A demonstrated early antitumor activity in heavily pretreated patients with relapsed/refractory multiple myeloma in whom previous CAR T-cell therapy and/or transplant had failed, according to preliminary data from the phase 1 MELANI-01 trial.

Isatuximab, Melflufen Combos Seek to Move the Needle in Relapsed/Refractory Myeloma

May 14th 2021

Novel combinations are paramount for patients with relapsed/refractory multiple myeloma who are in second relapse or beyond; some isatuximab-irfc–containing regimens have the potential to move to the frontline setting and combining melphalan flufenamide with proteasome inhibitors and anti-CD38 monoclonal antibodies is an active area of interest.

Dr. Landgren on the Clinical Impact of KRd-D in Multiple Myeloma

May 13th 2021

Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.